查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924628

禽流感疫苗市场依疫苗类型、动物种类、用途、给药途径及病毒株划分－2026-2032年全球预测

Avian Influenza Vaccines Market by Vaccine Type, Animal Type, Application, Administration Route, Virus Strain - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年禽流感疫苗市值为 7.7802 亿美元，预计到 2026 年将成长至 8.5138 亿美元，年复合成长率为 9.98%，到 2032 年将达到 15.1511 亿美元。

关键市场统计数据
基准年 2025 7.7802亿美元
预计年份：2026年 8.5138亿美元
预测年份 2032 15.1511亿美元
复合年增长率 (%) 9.98%

从战略角度分析当前的禽流感疫苗环境，凸显了病原体的复杂性、创新驱动因素以及跨部门行动的必要性。

禽流感疫苗领域正处于一个转折点，病原体动态变化、疫苗科学进步以及日益增长的地缘政治压力正在交汇融合，重塑整个生产系统的优先事项。人们对通用感染疾病传播、家禽和水禽疫情反覆爆发以及监管力度加大的担忧日益加剧，使得疫苗接种策略成为生产商、动物保健公司和公共卫生机构的当务之急。同时，重组平台技术的创新、递送方式的改进以及DIVA（同步诊断和疫苗接种）製剂的研发，正在拓展可用于平衡疾病控制与维护贸易路线的工具。

概述技术、营运和监管方面的变化，以及「同一健康」理念的演变，如何重塑疫苗的研发、分发和策略决策。

多项变革正在发生，重塑禽流感防治产业的方法。其中最重要的是平台技术的快速成熟，重组疫苗和载体疫苗能够更快地更新抗原，并在安全性和DIVA相容性方面展现出潜在优势，从而有助于保障贸易的持续性。同时，製剂科学的进步推动了耐热製剂和新型佐剂系统的研发，降低了对低温运输的依赖，并支持在各种生产环境下进行疫苗接种。这些技术进步与营运方式的变革相辅相成。製造商正在探索区域灌装基地和战略合作伙伴关係，以缩短前置作业时间，而合约研发生产机构（CDMO）也越来越多地提供灵活的规模化生产服务。

对近期关税措施对禽类疫苗生态系统供应链经济、筹资策略和国内生产奖励的影响全面评估

关税和贸易措施的实施会对疫苗供应链、原料采购和分销经济产生连锁反应。进口原料、佐剂和包装材料的关税上调通常会增加单位生产成本，这可能会加速本地化和替代筹资策略的需求。对于依赖外部供应商提供专用试剂、抗原生产基材和低温运输设备的製造商而言，关税造成的价格不确定性往往会导致库存调整、供应商合约重新谈判以及全球采购安排的策略性重新评估。

对产品动物群体管理和病毒株细分的详细检验揭示了其对製剂监管策略和现场部署的影响。

有效的细分提供了必要的分析粒度，使产品设计和商业策略能够与最终用户的需求保持一致。区分疫苗类型——灭活疫苗、减毒活病毒疫苗、重组疫苗和次单位疫苗——有助于选择安全性、抗原更新频率和监管申报结构。虽然重组疫苗和次单元疫苗在抗原保真度和DIVA标记整合方面具有优势，但由于其安全性和物流方面的成熟性，传统的灭活疫苗仍然被广泛使用。按物种进行细分，例如肉鸡、蛋鸡和水禽，突显了不同物种在性能和运作重点方面的差异。肉鸡养殖系统优先考虑快速起效和经济高效的大规模接种，而蛋鸡养殖系统则强调长期免疫和鸡蛋安全，水禽则需要适合不同饲养环境和迁徙特性的配方和接种方法。

生产系统、监管安排、监测能力和生产准备的区域分析突显了全球疫苗部署的趋势。

区域趋势在疫苗政策、生产策略和分销物流的製定中发挥着至关重要的作用。在美洲，商业性家禽系统与兽医服务部门之间的密切合作，促使人们更加重视生产规模的疫苗接种计划，这些计划得到了私营部门投资和区域诊断网络的支持，以支持快速识别毒株。贸易关係和出口导向影响疫苗的选择和文件要求，相关人员需要在生物安全措施和市场进入要求之间取得平衡。

透过分析竞争定位、伙伴关係模式、智慧财产权重点和附加价值服务策略，可以界定禽流感疫苗供应商生态系统。

禽流感疫苗领域的竞争格局复杂，全球动物用药品企业、专业生技公司和契约製造组织（CMO）均采取差异化策略。主要企业致力于提昇平台的多功能性和株更新能力，同时积极取得抗原表达系统、佐剂技术和DIVA相容标记物的智慧财产权。中型企业和新兴企业则倾向于专注于自身优势，例如热稳定性、替代剂型以及针对特定地区的抗原组合，以适应特定的生产系统和法规环境。

为製造商、监管机构和生产商提供切实可行的策略性倡议，以增强疫苗专案的韧性、灵活性和全面价值交付能力

行业领导者应推进切实可行的行动计划，以增强应对生物学不确定性和商业性复杂性的能力。首先，应优先投资于包含DIVA标记的灵活疫苗平台，以实现抗原的快速更新并保障贸易的持续性。除了这种技术灵活性之外，还应投资耐热配方和佐剂优化，以扩大疫苗在不同生产环境中的适用性。其次，应实现供应商和製造地的多元化，以降低对单一来源的依赖以及关税波动的影响。这包括策略性地利用区域填充和包装合作伙伴以及产能共用机制。

我们采用透明的混合方法研究途径，整合相关人员访谈、科学文献、专利和监管分析以及基因组监测，以确保研究结果具有可操作性。

本分析采用混合方法，整合了一手和二手研究证据，旨在确保分析结果的稳健性和相关性。研究包括对兽医、家禽养殖户、监管专家和生产企业高管进行结构化访谈，以了解实际营运和策略重点。二手资讯来源包括关于疫苗平台和免疫学的同行评审文献、监管指导文件、专利概况评估以及描述剂量和配方方法的技术文件。此外，还分析了基因组监测报告和疫情记录，以更好地理解病毒株的相关讨论，并为抗原漂移和毒株选择的讨论提供依据。

一份权威的综合分析报告，重点强调了平台柔软性、区域製造韧性和综合监测，以提高疫苗有效性和疾病控制。

总之，在科学创新、贸易趋势变化和日益增强的监测需求的共同影响下，禽流感疫苗领域正在迅速发展。相关人员将技术投资与务实的部署策略相结合，并优先考虑平台柔软性、热稳定性以及DIVA（分离检测和免疫）能力，将更有利于应对新出现的毒株，并为贸易敏感型市场提供支持。在营运方面，实现製造地多元化并加强与供应商的关係可以减轻政策主导的成本波动的影响，并确保在疫情爆发期间具备所需的敏捷应对能力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依疫苗类型分類的禽流感疫苗市场

  • 灭活疫苗
  • 减毒活病毒疫苗
  • 重组疫苗
  • 次单位疫苗

9. 依动物类型分類的禽流感疫苗市场

  • 肉鸡
  • 产蛋母鸡
  • 水禽

第十章 依应用分類的禽流感疫苗市场

  • 为了预防
    • 加强疫苗接种
    • 基本的
  • 治疗

11. 依给药途径分類的禽流感疫苗市场

  • 饮用水
  • 肌肉内注射
  • 喷
  • 皮下注射

12. 按病毒株分類的禽流感疫苗市场

  • H5N1
  • H7N9
  • H9N2

第十三章 各地区禽流感疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 禽流感疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国禽流感疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国禽流感疫苗市场

第十七章：中国禽流感疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AdvaCare Pharma Pte. Ltd.
  • AstraZeneca PLC
  • Bharat Biotech International Limited
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • CAVAC SA
  • Ceva Sante Animale SA
  • Chengdu Tech-bank Biological Products Co., Ltd
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Elanco Animal Health Incorporated
  • Emergent BioSolutions Inc.
  • Fatro SPA
  • GlaxoSmithKline plc
  • Hester Biosciences Limited
  • HIPRA SL
  • Johnson & Johnson Private Limited
  • Medion SA
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Phibro Animal Health Corporation
  • QYH Biotech Company Limited
  • Sanofi SA
  • Seqirus UK Limited
  • Serum Institute of India Private Limited
  • Sinovac Biotech Ltd.
  • Vaxart, Inc.
  • Virbac SA
  • Zoetis Inc
Product Code: MRR-7A380DA7C3E3

The Avian Influenza Vaccines Market was valued at USD 778.02 million in 2025 and is projected to grow to USD 851.38 million in 2026, with a CAGR of 9.98%, reaching USD 1,515.11 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 778.02 million
Estimated Year [2026] USD 851.38 million
Forecast Year [2032] USD 1,515.11 million
CAGR (%) 9.98%

A strategic framing of the current avian influenza vaccine environment highlighting pathogen complexity innovation levers and cross-sector imperatives for action

The avian influenza vaccine landscape is at an inflection point, defined by evolving pathogen dynamics, advances in vaccine science, and shifting geopolitical pressures that collectively reshape priorities across production systems. Rising concerns about zoonotic spillover, recurrent outbreaks in poultry and waterfowl, and heightened regulatory scrutiny have made vaccination strategy an operational imperative for producers, animal health companies, and public health authorities. At the same time, innovations in recombinant platforms, improved delivery modalities, and the pursuit of DIVA-compatible formulations are expanding the toolkit available to control disease while preserving trade channels.

This introduction synthesizes the confluence of drivers that demand renewed strategic focus: pathogen diversity and antigenic drift require flexible vaccine platforms; supply chain resilience and cost containment drive regional manufacturing and alternative administration strategies; and integrated surveillance with vaccine policy supports timely interventions. By framing the current environment in this way, stakeholders can prioritize investments that balance short-term outbreak response with longer-term capability building. As the sector navigates both biological complexity and commercial constraints, a coordinated approach that brings together vaccine developers, poultry integrators, regulators, and diagnostic providers will be essential to reduce disease burden and protect both animal and public health.

An overview of technological operational regulatory and One Health transformations that are reshaping vaccine development distribution and strategic decision-making

Several transformative shifts are redefining how the industry approaches prevention and control of avian influenza. Foremost among these is the rapid maturation of platform technologies; recombinant and vectored vaccines now enable faster antigen updates and offer potential advantages in safety and DIVA compatibility, which can facilitate trade continuity. Concurrently, formulation science has produced more thermostable preparations and alternative adjuvant systems that reduce cold-chain dependency and support administration in diverse production settings. These technological advances are complemented by operational shifts: manufacturers are exploring regional fill-and-finish hubs and strategic partnerships to shorten lead times, while contract development and manufacturing organizations are increasingly providing flexible scale-up services.

On the policy front, regulatory agencies are adapting to expedited pathways for emergency responses and harmonizing frameworks for veterinary biologics, creating opportunities for faster authorizations when supported by robust safety and efficacy data. Digital transformation is another pivotal trend; integrated surveillance systems and genomic sequencing pipelines enable near-real-time detection of emerging strains and inform vaccine strain selection. Finally, a One Health perspective is gaining traction, coordinating efforts across animal health, public health, and environmental sectors to align vaccination strategies with broader disease prevention and biosecurity measures. Together, these shifts are transforming vaccine development timelines, distribution logistics, and decision-making processes across the value chain.

A comprehensive assessment of how recent tariff measures alter supply chain economics procurement strategies and domestic manufacturing incentives across the avian vaccine ecosystem

The introduction of tariffs and trade measures can have cascading effects across vaccine supply chains, input sourcing, and the economics of distribution. Increased duties on imported raw materials, adjuvants, or packaging components typically raise production unit costs and may accelerate the case for localized manufacturing or alternative sourcing strategies. For manufacturers that rely on specialized reagents, antigen production substrates, or cold-chain equipment from external suppliers, tariff-driven price uncertainty often triggers inventory adjustments, renegotiation of supplier contracts, and a strategic reassessment of global procurement footprints.

Tariff policies also influence export competitiveness and bilateral trade dynamics for vaccine producers that serve international poultry markets. When duties affect the relative cost of exported vaccines or vaccine-enabled poultry products, producers and exporters reassess destination strategies and may prioritize markets with preferential treatment or lower regulatory barriers. Policymakers and industry leaders respond by considering mitigating measures such as supply chain diversification, increased investment in domestic fill-and-finish capabilities, and public-private collaboration to insulate critical inputs from policy volatility. In parallel, contract manufacturers and distributors adapt commercial terms and logistics planning to maintain continuity of supply in the face of shifting trade costs. These responses collectively reshape capital allocation, operational priorities, and partnership models across the sector.

A nuanced examination of product animal population administration and viral strain segmentation revealing implications for formulation regulatory strategy and field deployment

Meaningful segmentation provides the analytical granularity required to align product design and commercial strategy with end-user needs. Vaccine type distinctions-across inactivated vaccine, live attenuated vaccine, recombinant vaccine, and subunit vaccine-drive choices related to safety profile, antigen update cadence, and regulatory dossier composition; recombinant and subunit approaches offer advantages for antigen precision and DIVA marker incorporation, whereas traditional inactivated formats remain widely used for their established safety and logistics. Animal type segmentation, encompassing broiler chickens, layer hens, and waterfowl, highlights divergent performance and operational priorities: broiler systems prioritize rapid onset and cost-effective mass administration, layer systems emphasize long-term immunity and egg safety considerations, and waterfowl require formulations and delivery methods suited to different husbandry and migratory contexts.

Application nuances differentiate preventive from therapeutic use, with preventive strategies including primary immunization and booster programs designed to maintain flock immunity over production cycles, while therapeutic approaches focus on supportive therapies that mitigate clinical impact during outbreaks. Administration route analysis-covering drinking water, intramuscular, spray, and subcutaneous delivery-reveals operational trade-offs between labor intensity, stress on birds, and uniformity of dosing; drinking water and spray routes facilitate mass application and reduce handling, whereas intramuscular and subcutaneous routes support targeted dosing with potential for higher individual immunogenicity. Virus strain segmentation across H5N1, H7N9, and H9N2 underscores the need for strain-matched antigen selection and robust surveillance to detect antigenic drift. Integrating these segmentation lenses enables developers and producers to tailor product portfolios, prioritize regulatory pathways, and design distribution and administration protocols that reflect heterogeneous field realities.

A regional analysis of production systems regulatory coordination surveillance capacity and manufacturing responses shaping vaccine adoption across global geographies

Regional dynamics play a decisive role in shaping vaccine policy, manufacturing strategy, and distribution logistics. In the Americas, strong integration between commercial poultry systems and veterinary services has led to a growing emphasis on production-scale vaccination programs, bolstered by private sector investment and regional diagnostic networks that support timely strain identification. Trade relationships and export orientation influence vaccine selection and documentation needs, with stakeholders balancing biosecurity measures against market access requirements.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with diverse production contexts, from highly integrated industrial flocks to smallholder operations. This heterogeneity drives demand for both advanced platform vaccines and affordable, easy-to-administer formulations. Collaborative surveillance programs and cross-border coordination are increasingly prioritized to manage migratory bird pathways and transboundary spread. In Asia-Pacific, high-density poultry populations, frequent interactions with wild waterfowl, and active research ecosystems have accelerated adoption of recombinant platforms and localized manufacturing investments to support rapid response capacity. Regional authorities and industry partners often integrate vaccination with broader biosecurity campaigns and community-level outreach, reflecting a blend of commercial and public health objectives. Understanding these regional characteristics is essential for aligning R&D, regulatory engagement, and distribution strategies to local priorities and constraints.

An analysis of competitive positioning partnership models intellectual property focus and value-added service strategies defining the avian influenza vaccine supplier ecosystem

Competitive dynamics in the avian influenza vaccine domain are characterized by a mix of global animal health divisions, specialized biotech firms, and contract manufacturing organizations pursuing differentiated strategies. Leading players tend to invest in platform versatility and strain update capabilities, securing intellectual property around antigen expression systems, adjuvant technologies, and DIVA-compatible markers. Mid-sized and emerging companies often focus on niche advantages such as thermostability, alternative administration formats, or regionally tailored antigen combinations to serve specific production systems or regulatory environments.

Partnerships and licensing arrangements are common, enabling smaller innovators to leverage the regulatory experience and distribution networks of larger incumbents, while larger firms benefit from agile R&D and specialized technologies. Contract manufacturers and fill-and-finish providers have become strategic assets for rapid scale-up and for de-risking capital-intensive production expansions. Across the competitive landscape, companies are also placing greater emphasis on services that complement vaccines-diagnostics for strain typing, cold-chain logistics solutions, and digital monitoring tools-to offer integrated value propositions to poultry integrators and veterinary networks. These combined offerings shape procurement decisions and create barriers for entrants that lack end-to-end capabilities.

A pragmatic set of strategic initiatives for manufacturers regulators and producers to enhance resilience agility and integrated value delivery in vaccine programs

Industry leaders should pursue a set of pragmatic actions to navigate biological uncertainty and commercial complexity while strengthening resilience. First, prioritize investment in flexible vaccine platforms that facilitate rapid antigen updates and incorporate DIVA markers to support trade continuity. This technological agility should be complemented by investments in thermostable formulations and adjuvant optimization to broaden applicability across diverse production environments. Second, diversify supplier and manufacturing footprints to reduce exposure to single-source inputs and tariff-induced disruptions, including strategic use of regional fill-and-finish partners and capacity-sharing arrangements.

Third, proactively engage with regulatory authorities and regional harmonization initiatives to streamline approval pathways for emergency strain updates and to align safety and efficacy endpoints. Fourth, integrate surveillance and genomic intelligence into product development pipelines to ensure antigen selection is informed by real-time epidemiology. Fifth, enhance value propositions by bundling vaccines with diagnostics, administration tools, and training programs for field personnel to ensure correct use and to improve uptake. Finally, adopt commercial models that reflect customer segments-offering different formulations and delivery formats for broilers, layers, and waterfowl-and create pricing and distribution strategies that account for regional infrastructure realities. These actions balance near-term outbreak readiness with sustainable capability building.

A transparent mixed-methods research approach combining stakeholder interviews scientific literature patent and regulatory analysis and genomic surveillance to ensure actionable findings

This analysis synthesizes primary and secondary evidence using a mixed-methods approach designed to ensure robustness and relevance. The research incorporated structured interviews with veterinarians, poultry producers, regulatory experts, and manufacturing executives to capture operational realities and strategic priorities. Secondary inputs included peer-reviewed literature on vaccine platforms and immunology, regulatory guidance documents, patent landscape assessments, and technical dossiers describing administration and formulation approaches. Genomic surveillance reports and outbreak records were analyzed to contextualize virus strain considerations and to inform discussions about antigenic drift and strain selection.

Data were triangulated across sources to validate findings, and analytical frameworks were applied to assess clinical, operational, and commercial implications. Where gaps existed, targeted expert consultations were used to refine interpretations and to identify practical constraints in field deployment. Limitations of the methodology include variability in reporting standards across regions and conditional access to proprietary commercial data, which were mitigated through cross-validation and sensitivity checks. Overall, the methodology emphasizes transparency, source triangulation, and a pragmatic focus on actionable implications for stakeholders across the value chain.

A conclusive synthesis emphasizing platform flexibility regional manufacturing resilience and integrated surveillance to enhance vaccine effectiveness and disease control

In conclusion, the avian influenza vaccine landscape is rapidly evolving under the combined influence of scientific innovation, shifting trade dynamics, and intensified surveillance needs. Stakeholders that align technological investments with pragmatic deployment strategies-prioritizing platform flexibility, thermostability, and DIVA capability-will be better positioned to respond to strain emergence and to support trade-sensitive markets. Operationally, diversifying manufacturing footprints and strengthening supplier relationships will mitigate the impacts of policy-driven cost volatility and provide the agility needed during outbreak responses.

Equally important is the integration of surveillance intelligence into the vaccine lifecycle and the development of end-to-end solutions that include diagnostics, training, and logistics to maximize field effectiveness. By coordinating regulatory engagement, investing in regional capabilities, and adopting differentiated product and commercial strategies for broilers, layers, and waterfowl, the industry can reduce disease impact and protect both commercial interests and public health. The path forward requires collaboration across private and public sectors, a sustained focus on platform and operational resilience, and a commitment to translating scientific advances into field-ready solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Avian Influenza Vaccines Market, by Vaccine Type

  • 8.1. Inactivated Vaccine
  • 8.2. Live Attenuated Vaccine
  • 8.3. Recombinant Vaccine
  • 8.4. Subunit Vaccine

9. Avian Influenza Vaccines Market, by Animal Type

  • 9.1. Broiler Chickens
  • 9.2. Layer Hens
  • 9.3. Waterfowl

10. Avian Influenza Vaccines Market, by Application

  • 10.1. Preventive
    • 10.1.1. Booster
    • 10.1.2. Primary
  • 10.2. Therapeutic

11. Avian Influenza Vaccines Market, by Administration Route

  • 11.1. Drinking Water
  • 11.2. Intramuscular
  • 11.3. Spray
  • 11.4. Subcutaneous

12. Avian Influenza Vaccines Market, by Virus Strain

  • 12.1. H5N1
  • 12.2. H7N9
  • 12.3. H9N2

13. Avian Influenza Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Avian Influenza Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Avian Influenza Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Avian Influenza Vaccines Market

17. China Avian Influenza Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AdvaCare Pharma Pte. Ltd.
  • 18.6. AstraZeneca PLC
  • 18.7. Bharat Biotech International Limited
  • 18.8. BioNTech SE
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. CAVAC S.A.
  • 18.11. Ceva Sante Animale S.A.
  • 18.12. Chengdu Tech-bank Biological Products Co., Ltd
  • 18.13. CSL Limited
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Elanco Animal Health Incorporated
  • 18.16. Emergent BioSolutions Inc.
  • 18.17. Fatro S.P.A.
  • 18.18. GlaxoSmithKline plc
  • 18.19. Hester Biosciences Limited
  • 18.20. HIPRA S.L.
  • 18.21. Johnson & Johnson Private Limited
  • 18.22. Medion S.A.
  • 18.23. Merck & Co., Inc.
  • 18.24. Mitsubishi Tanabe Pharma Corporation
  • 18.25. Moderna, Inc.
  • 18.26. Novavax, Inc.
  • 18.27. Pfizer Inc.
  • 18.28. Phibro Animal Health Corporation
  • 18.29. QYH Biotech Company Limited
  • 18.30. Sanofi S.A.
  • 18.31. Seqirus UK Limited
  • 18.32. Serum Institute of India Private Limited
  • 18.33. Sinovac Biotech Ltd.
  • 18.34. Vaxart, Inc.
  • 18.35. Virbac S.A.
  • 18.36. Zoetis Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AVIAN INFLUENZA VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AVIAN INFLUENZA VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 127. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 148. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 155. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)